1. Home
  2. NMG vs CTMX Comparison

NMG vs CTMX Comparison

Compare NMG & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nouveau Monde Graphite Inc.

NMG

Nouveau Monde Graphite Inc.

N/A

Current Price

$1.45

Market Cap

592.4M

ML Signal

N/A

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

N/A

Current Price

$3.17

Market Cap

642.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NMG
CTMX
Founded
2011
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
592.4M
642.2M
IPO Year
2015
2015

Fundamental Metrics

Financial Performance
Metric
NMG
CTMX
Price
$1.45
$3.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
10
Target Price
$5.75
$12.10
AVG Volume (30 Days)
848.5K
3.8M
Earning Date
05-13-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$1.37
$1.72
52 Week High
$6.06
$8.21

Technical Indicators

Market Signals
Indicator
NMG
CTMX
Relative Strength Index (RSI) 31.51 45.83
Support Level N/A $3.06
Resistance Level $2.42 $3.49
Average True Range (ATR) 0.09 0.16
MACD -0.00 0.05
Stochastic Oscillator 13.89 83.33

Price Performance

Historical Comparison
NMG
CTMX

About NMG Nouveau Monde Graphite Inc.

Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: